PL2233150T3 - Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek - Google Patents

Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek

Info

Publication number
PL2233150T3
PL2233150T3 PL10005293T PL10005293T PL2233150T3 PL 2233150 T3 PL2233150 T3 PL 2233150T3 PL 10005293 T PL10005293 T PL 10005293T PL 10005293 T PL10005293 T PL 10005293T PL 2233150 T3 PL2233150 T3 PL 2233150T3
Authority
PL
Poland
Prior art keywords
epo
liver
cells
treatment
tissue
Prior art date
Application number
PL10005293T
Other languages
English (en)
Inventor
Augustinus Bader
Original Assignee
Bader
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10361813A external-priority patent/DE10361813A1/de
Priority claimed from EP03029961A external-priority patent/EP1550715A1/de
Application filed by Bader filed Critical Bader
Publication of PL2233150T3 publication Critical patent/PL2233150T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
PL10005293T 2003-12-30 2004-12-30 Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek PL2233150T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10361813A DE10361813A1 (de) 2003-12-30 2003-12-30 Verfahren zur Regeneration von Gewebe
EP03029961A EP1550715A1 (de) 2003-12-30 2003-12-30 Verfahren zur Regenation von Gewebe
EP10005293.5A EP2233150B1 (de) 2003-12-30 2004-12-30 Erythropoietin zur Anwendung bei der Behandlung von Wunden oder der Transplantation von Zellen

Publications (1)

Publication Number Publication Date
PL2233150T3 true PL2233150T3 (pl) 2017-06-30

Family

ID=34740522

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10005293T PL2233150T3 (pl) 2003-12-30 2004-12-30 Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek
PL04804424T PL1699915T3 (pl) 2003-12-30 2004-12-30 Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04804424T PL1699915T3 (pl) 2003-12-30 2004-12-30 Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej

Country Status (14)

Country Link
US (2) US7910547B2 (pl)
EP (2) EP1699915B1 (pl)
JP (2) JP4903580B2 (pl)
AT (1) ATE469654T1 (pl)
AU (2) AU2004309083B2 (pl)
BR (1) BRPI0418326A (pl)
CA (1) CA2550301A1 (pl)
DE (1) DE502004011252D1 (pl)
DK (2) DK2233150T3 (pl)
ES (2) ES2346226T3 (pl)
PL (2) PL2233150T3 (pl)
PT (1) PT1699915E (pl)
RU (2) RU2392314C2 (pl)
WO (1) WO2005063965A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026480A1 (de) * 2000-05-29 2001-12-13 Augustinus Bader Verfahren zur Herstellung eines empfängerspezifischen Gewebe-Transplantats oder -Implantats
PL2233150T3 (pl) 2003-12-30 2017-06-30 Bader Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek
JP4982841B2 (ja) * 2005-10-12 2012-07-25 国立大学法人名古屋大学 再生医療骨組成物
US20080107632A1 (en) * 2006-09-06 2008-05-08 Henrich Cheng Fibrin glue composition for repairing nerve damage and methods thereof
JP4696247B2 (ja) * 2006-12-11 2011-06-08 国立大学法人 筑波大学 肝線維化抑制剤
JP5098018B2 (ja) * 2007-03-06 2012-12-12 国立大学法人 筑波大学 肝炎治療剤
AR065613A1 (es) * 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
EP2192907B1 (en) 2007-08-16 2018-04-18 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic applications
BRPI0821814A2 (pt) * 2007-12-28 2015-06-16 Heraeus Kulzer Gmbh Uso e formulação tópica de eritropoietina para a cicatrização da pele
WO2009089324A1 (en) * 2008-01-08 2009-07-16 Yale University Compositions and methods for promoting patency of vascular grafts
JP5829400B2 (ja) * 2008-01-24 2015-12-09 レメドー バイオメッド リミテッド 骨再生のためのエリスロポイエチンおよびフィブロネクチン組成物
US8470369B2 (en) * 2008-03-10 2013-06-25 Marfly 2, L.P Bone paste composition
EP2273997B1 (de) * 2008-03-31 2016-01-13 Augustinus Bader Verfahren und zusammensetzung zur regeneration von gewebe mit hilfe von stamm- oder knochenmarkzellen
RU2531046C2 (ru) 2008-12-24 2014-10-20 Аугустинус БАДЕР Быстрое получение и применение искусственных тканей и каркасов в качестве индивидуальных имплантатов
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
WO2011102991A1 (en) * 2010-02-22 2011-08-25 President And Fellows Of Harvard College Methods of generating engineered innervated tissue and uses thereof
BR112012021179A2 (pt) * 2010-02-23 2015-09-15 Sebana Medical Ltd método para aprimorar a sobrevivência da gordura adiposa em um paciente que necessite da mesma, uso de eritropoietina e composição farmacêutica
WO2011153512A2 (en) * 2010-06-03 2011-12-08 Indiana University Research And Technology Corporation Use of compounds with thrombopoietic activity to promote bone growth and healing
WO2012003960A1 (en) 2010-07-06 2012-01-12 Augustinus Bader Topical application of erythropoietin for the treatment of eye disorders and injuries
WO2012031778A1 (de) 2010-09-12 2012-03-15 Augustinus Bader Verwendung von erythropoietin bei der heilung von wunden oder gewebedefekten ohne narbenbildung
WO2012148200A2 (ko) * 2011-04-26 2012-11-01 아주대학교 산학협력단 허혈성 혈관 질환 치료시술 보조용 조성물
WO2017117229A1 (en) 2015-12-30 2017-07-06 Wake Forest University Health Sciences Tissue-engineered gut-sphincter complexes and methods of making the same
CA2863310C (en) * 2012-01-31 2018-11-13 Wake Forest University Health Sciences Innervation of engineered structures
US11311367B2 (en) 2012-01-31 2022-04-26 Wake Forest University Health Sciences Tissue-engineered gut-sphincter complexes and methods of making the same
EP3712612A1 (en) 2013-01-03 2020-09-23 Brigham and Women's Hospital, Inc. System and method for producing target biological substances
RU2522816C1 (ru) * 2013-02-12 2014-07-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Композиция для клеточно-заместительной терапии дефектов мягких тканей
US10590373B2 (en) 2014-03-31 2020-03-17 Brigham And Women's Hospital, Inc. Systems and methods for biomimetic fluid processing
JP2016067312A (ja) * 2014-09-30 2016-05-09 株式会社ジーシー 軟骨分化培養液、及び軟骨組織
RU2582948C1 (ru) * 2014-10-23 2016-04-27 Ренат Рашитович Ахмеров Способ волюмизации мягких тканей с помощью термически обработанной тромбоцитарной аутологичной плазмы
US10232048B1 (en) * 2014-11-18 2019-03-19 Divine Api-Logics, LLC Apitherapy method and composition
JP6800984B2 (ja) * 2015-10-05 2020-12-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 軟骨傷害の検出及び処置のためのマイクロ並びにナノデバイス
CN108601863A (zh) 2015-12-11 2018-09-28 国家儿童医院研究所 用于优化的患者特异性组织工程化血管移植物的系统和方法
WO2017104725A1 (ja) * 2015-12-16 2017-06-22 第一三共株式会社 創傷治療剤
RU2638796C1 (ru) * 2016-08-05 2017-12-15 Общество с ограниченной ответственностью "Покровский банк стволовых клеток" Способ получения двухкомпонентного препарата для лечения повреждения суставов путем малоинвазивного введения в суставную сумку и препарат, полученный этим способом
ES2952448T3 (es) 2016-11-10 2023-10-31 Asc Regenity Ltd Formulaciones cosméticas para aplicaciones tópicas que contienen moléculas derivadas de eritropoyetina
RU2648869C1 (ru) * 2017-04-03 2018-03-28 Анатолий Владимирович Толстов Способ лечения локальных ожоговых ран II-III А степени
RU2650214C1 (ru) * 2017-04-04 2018-04-11 федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) Способ комбинированной остеопластической хирургии околоносовых пазух с использованием фактора роста
RU2666595C1 (ru) * 2017-09-26 2018-09-11 федеральное государственное бюджетное образовательное учреждение высшего образования Кубанский государственный медицинский университет Министерства Здравоохранения Российской Федерации ФГБОУ ВО КубГМУ Минздрава России Гидрогель для коррекции посттрепанационного дефекта черепа
WO2019183201A1 (en) * 2018-03-20 2019-09-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Regeneration of vital tooth pulp
US20210106718A1 (en) * 2019-10-14 2021-04-15 Board Of Regents, The University Of Texas System Mussel inspired nancomposite adhesives for biomedical applications
CN113521049A (zh) * 2021-07-29 2021-10-22 姚雷利 一种妊娠纹脱模修复方法
WO2023168153A1 (en) * 2022-03-03 2023-09-07 Fibrobiologics, Inc. Therapeutic use of fibroblasts to stimulate regeneration and repair of atrophied spleen
WO2023210713A1 (ja) * 2022-04-27 2023-11-02 国立大学法人京都大学 心外膜細胞再生促進剤および心外膜細胞の再生促進方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6008047A (en) 1993-04-08 1999-12-28 Livercell L.L.C. Cell culturing method and medium
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
ATE354377T1 (de) * 1993-12-02 2007-03-15 Max Delbrueck Centrum Antitumormittel, enthaltend ein zytostatikum und ein kontrastmittel
CZ221496A3 (en) 1994-02-14 1997-07-16 Zymogenetics Inc Haematopoetic protein, materials and processes for preparing thereof
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
CN1103782C (zh) 1994-03-31 2003-03-26 安姆根有限公司 单聚乙二醇化的mgdf多肽
US7008634B2 (en) * 1995-03-03 2006-03-07 Massachusetts Institute Of Technology Cell growth substrates with tethered cell growth effector molecules
US5879673A (en) 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
RU2115748C1 (ru) * 1996-11-19 1998-07-20 Открытое акционерное общество "АВИСМА титано-магниевый комбинат" Способ переработки отходящих газов магниевого производства
DE59803925D1 (de) 1997-06-27 2002-05-29 Augustinus Bader Bioartifizielles transplantat und verfahren zu seiner herstellung
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6776984B1 (en) * 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
AU6092900A (en) * 1999-07-14 2001-02-05 Board Of Trustees Of The Leland Stanford Junior University Animals comprising human hepatocellular tissue
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DE10034583A1 (de) 2000-07-14 2002-01-31 Axel Haverich Individuelle Venenklappenprothese
DE60137525D1 (de) * 2000-10-16 2009-03-12 Chugai Pharmaceutical Co Ltd Peg-modifiziertes erythropoietin
DE60144439D1 (de) 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20020187936A1 (en) * 2001-05-17 2002-12-12 Board Of Trustees For The University Of Illinois Methods of treating liver disease and liver damage with growth hormone and foxM1B
JP2004529740A (ja) * 2001-06-15 2004-09-30 ジョーンズ ホプキンズ シンガポール ピーティーイー リミテッド 生体機能繊維
JP4065846B2 (ja) * 2001-11-16 2008-03-26 チルドレンズ メディカル センター コーポレーション 組織工学処理された女性の生殖器官の創製
EP1517988B1 (de) * 2002-06-20 2013-05-08 Augustinus Bader Verwendung von Erythropoietin zur Geweberegeneration in vivo
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
BR0317752A (pt) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
DE10303584A1 (de) * 2003-01-30 2004-08-12 Stauss, Robert, Dr. Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
PL2233150T3 (pl) 2003-12-30 2017-06-30 Bader Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek

Also Published As

Publication number Publication date
WO2005063965A1 (de) 2005-07-14
RU2006120458A (ru) 2008-02-10
EP2233150A2 (de) 2010-09-29
ES2346226T3 (es) 2010-10-13
DE502004011252D1 (de) 2010-07-15
AU2011200538A1 (en) 2011-03-03
RU2542391C2 (ru) 2015-02-20
AU2011200538B2 (en) 2012-02-23
JP4903580B2 (ja) 2012-03-28
EP1699915A1 (de) 2006-09-13
PL1699915T3 (pl) 2010-11-30
US7910547B2 (en) 2011-03-22
EP1699915B1 (de) 2010-06-02
BRPI0418326A (pt) 2007-05-02
DK1699915T3 (da) 2010-09-13
AU2004309083A1 (en) 2005-07-14
RU2010105646A (ru) 2011-08-27
US20110172150A1 (en) 2011-07-14
ES2606068T3 (es) 2017-03-17
JP2012067117A (ja) 2012-04-05
JP2007517001A (ja) 2007-06-28
ATE469654T1 (de) 2010-06-15
RU2392314C2 (ru) 2010-06-20
CA2550301A1 (en) 2005-07-14
PT1699915E (pt) 2010-08-31
EP2233150A3 (de) 2013-01-09
EP2233150B1 (de) 2016-09-07
US20080031850A1 (en) 2008-02-07
AU2004309083B2 (en) 2010-11-11
DK2233150T3 (en) 2016-12-12

Similar Documents

Publication Publication Date Title
PL2233150T3 (pl) Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek
Marolt Presen et al. Mesenchymal stromal cell-based bone regeneration therapies: from cell transplantation and tissue engineering to therapeutic secretomes and extracellular vesicles
KR101422689B1 (ko) 콜라겐, 히알루론산 유도체 및 포유류의 탯줄 유래 줄기세포를 포함하는 연골세포치료제
Navsaria et al. Culturing skin in vitro for wound therapy
JPS59192364A (ja) 軟骨および骨の修復方法
DE69327544T2 (de) Mischungen zum schutz und regenierung von geweben
CA2387542A1 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
JP2004537998A (ja) 細胞培養および組織工学のためのリシルオキシダーゼ阻害剤の使用
HK1062537A1 (en) Methods and compositions for healing and repair of articular cartilage
JP2006510399A (ja) 未分化間葉細胞を用いた組織の治療
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
JP2002521440A (ja) 骨または軟骨細胞および組織の治療用クレアチン化合物の使用
EP1077254A3 (en) Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
AU5283890A (en) Fibroblast growth factor (fgf)-based stabilized compositions
Wilkes et al. The long-term survival of onlay bone grafts—a comparative study in mature and immature animals
NO924323L (no) Nye hybridtransformerende vekstfaktorer
EP1405906A4 (en) SCHWANN CELLS FROM INTERSTITIAL MYELOID CELLS
PT941329E (pt) Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
IL144523A0 (en) Method and compositions for healing and repair of articular cartilage
Tan et al. Low-intensity pulsed ultrasound (LIPUS) and pulsed electromagnetic field (PEMF) treatments affect degeneration of cultured articular cartilage explants
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
Ribeiro et al. Tissue engineering in plastic surgery-what has been done
Malakhov et al. Preliminary report of the clinical use of cultured allogeneic keratinocytes
Tamimi et al. Progression course in the birth parturition waste materials toward application in tissue engineering-based approaches